Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Investment analysts at Gabelli upped their FY2020 earnings per share estimates for Collegium Pharmaceutical in a research report issued on Thursday. Gabelli analyst K. Kedra now expects that the specialty pharmaceutical company will post earnings of $0.50 per share for the year, up from their previous estimate of $0.45. Gabelli also issued estimates for Collegium Pharmaceutical’s FY2021 earnings at $1.70 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 91.05% and a negative net margin of 1,319.39%. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million.

TRADEMARK VIOLATION NOTICE: “FY2020 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Gabelli (COLL)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.watchlistnews.com/fy2020-eps-estimates-for-collegium-pharmaceutical-inc-lifted-by-gabelli-coll/1474329.html.

A number of other brokerages have also recently commented on COLL. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target (down previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Wednesday, April 19th. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Jefferies Group LLC restated a “buy” rating and issued a $22.00 price target (down previously from $24.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 11th. Janney Montgomery Scott restated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Finally, ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Three equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company. Collegium Pharmaceutical has an average rating of “Hold” and a consensus target price of $21.33.

Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 3.19% on Friday, reaching $10.34. The company’s stock had a trading volume of 460,789 shares. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $20.55. The company’s 50-day moving average is $12.19 and its 200 day moving average is $11.98. The company’s market capitalization is $305.71 million.

Several hedge funds have recently added to or reduced their stakes in the company. American International Group Inc. boosted its stake in Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares in the last quarter. Macquarie Group Ltd. acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at about $127,000. Credit Suisse AG boosted its stake in Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 1,173 shares in the last quarter. Finally, UBS Group AG boosted its stake in Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares in the last quarter. Hedge funds and other institutional investors own 82.27% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.